



Figure S1 Model plots of PFS and OS. (A) PFS of CRCT; (B) PFS of RM; (C) OS of CRCT; (D) OS of RM. AFT, accelerated failure time model; PFS, progression-free survival; OS, overall survival; CRCT, copanlisib plus rituximab combination therapy; RM, rituximab monotherapy.

Table S1 Parametric survival distribution evaluated for PFS

Regimen	Model	AIC	BIC	R ²
CRCT	Weibull	1,067.59	0.55	0.976
	Lognormal	1,062.4	0.06	0.992
	Loglogistic*	1,061.73	0	0.973
	Exponential	1,072.87	0.69	0.976
	Gompertz	1,073.84	1.13	0.978
RM	Weibull	694.89	0.58	0.994
	Lognormal*	690.86	0	0.984
	Loglogistic	693.47	0.37	0.985
	Exponential	697.08	0.46	0.991
	Gompertz	697.91	1.01	0.995

*, the model was used to fit the Kaplan-Meier. PFS, progression-free survival; CRCT, copanlisib plus rituximab combination therapy; RM, rituximab monotherapy; AIC, Akaike information criterion; BIC, Bayesian information criterion; R², goodness of fit.

Table S2 Parametric survival distributions evaluated for OS

Regimen	Model	AIC	BIC	R ²
CRCT	Weibull	519.44	1.08	0.973
	Lognormal*	517.3	0	0.980
	Loglogistic	518.89	0.97	0.975
	Exponential	517.56	0.31	0.967
	Gompertz	519.37	1.06	0.978
RM	Weibull	248.63	0.58	0.964
	Lognormal*	247.15	0	0.980
	Loglogistic	248.2	0.41	0.969
	Exponential	254.5	1.71	0.928
	Gompertz	251.81	1.84	0.951

*, the model was used to fit the Kaplan-Meier. OS, overall survival; CRCT, copanlisib plus rituximab combination therapy; RM, rituximab monotherapy; AIC, Akaike information criterion; BIC, Bayesian information criterion; R², goodness of fit.

Table S3 Parametric survival distributions evaluated for PFS in FL

Regimen	Model	AIC	BIC	R ²
CRCT-FL	Weibull	626.26	0.71	0.969
	Lognormal*	621.79	0	0.986
	Loglogistic	623.26	0.23	0.981
	Exponential	627.5	0.4	0.968
	Gompertz	629.17	1	0.973
RM-FL	Weibull*	433.01	0	0.973
	Lognormal	435.58	0.59	0.959
	Loglogistic	436.48	0.8	0.949
	Exponential	435.77	0.06	0.957
	Gompertz	433.14	0.03	0.981

*, the model was used to fit the Kaplan-Meier. PFS, progression-free survival; FL, follicular lymphoma; CRCT-FL, copanlisib plus rituximab combination therapy in follicular lymphoma; RM-FL, rituximab monotherapy in follicular lymphoma; AIC, Akaike information criterion; BIC, Bayesian information criterion; R², goodness of fit.

Table S4 Parametric survival distributions evaluated for PFS in MZL

Regimen	Model	AIC	BIC	R ²
CRCT-MZL	Weibull	208.14	1.45	0.953
	Lognormal*	205.1	0	0.978
	Loglogistic	206.1	0.48	0.967
	Exponential	208	0.34	0.946
	Gompertz	209.91	2.3	0.962
RM-MZL	Weibull	121.34	2.32	0.939
	Lognormal	119.95	1.18	0.952
	Loglogistic	120.58	1.69	0.953
	Exponential*	119.89	0	0.938
	Gompertz	121.85	2.75	0.944

*, the model was used to fit the Kaplan-Meier. PFS, progression-free survival; MZL, marginal zone lymphoma; CRCT-MZL, copanlisib plus rituximab combination therapy in marginal zone lymphoma; RM-MZL, rituximab monotherapy in marginal zone lymphoma; AIC, Akaike information criterion; BIC, Bayesian information criterion; R², goodness of fit.

Table S5 Parametric survival distributions evaluated for PFS in SLL

Regimen	Model	AIC	BIC	R ²
CRCT-SLL	Weibull	164.66	2.22	0.938
	Lognormal	161.34	0.2	0.959
	Loglogistic*	161.02	0	0.966
	Exponential	166.84	2.6	0.919
	Gompertz	168.1	4.3	0.923
RM-SLL	Weibull*	77.14	0	0.978
	Lognormal	77.41	0.52	0.980
	Loglogistic	78.1	0.92	0.974
	Exponential	79.95	2.85	0.936
	Gompertz	78.92	1.33	0.974

*, the model was used to fit the Kaplan-Meier. PFS, progression-free survival; SLL, small lymphocytic lymphoma; CRCT-SLL, copanlisib plus rituximab combination therapy in small lymphocytic lymphoma; RM-SLL, rituximab monotherapy in small lymphocytic lymphoma; AIC, Akaike information criterion; BIC, Bayesian information criterion; R², goodness of fit.

Table S6 Parametric survival distributions evaluated for PFS in LPL-WM

Regimen	Model	AIC	BIC	R ²
CRCT-LPL-WM	Weibull*	69.24	0	0.914
	Lognormal	69.53	0.41	0.915
	Loglogistic	69.54	0.41	0.898
	Exponential	70.57	0.33	0.808
	Gompertz	69.75	0.72	0.929
RM-LPL-WM	Weibull	70.67	3.27	0.969
	Lognormal	70.12	2.48	0.961
	Loglogistic	70.31	2.75	0.962
	Exponential*	69.16	0	0.961
	Gompertz	71.1	3.88	0.968

*, the model was used to fit the Kaplan-Meier. PFS, progression-free survival; LPL-WM, lymphoplasmacytic lymphoma-Waldenström macroglobulinaemia; CRCT-LPL-WM, copanlisib plus rituximab combination therapy in lymphoplasmacytic lymphoma-Waldenström macroglobulinaemia; RM-LPL-WM, rituximab monotherapy in lymphoplasmacytic lymphoma-Waldenström macroglobulinaemia; AIC, Akaike information criterion; BIC, Bayesian information criterion; R², goodness of fit.